GlassScriptPhysician profile
Tsujung Yang
NPI 1992250880
$2,979.64
in general payments reported to CMS, 2019-2025
12 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.49 · 2021: $125 · 2022: $42.02 · 2023: $103 · 2024: $2,197 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,418 · Food and Beverage: $1,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,418.35 |
| Food and Beverage | $1,358.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Wilson Cook Medical Incorporated | $1,420.92 | 2024 | Fusion |
| Cook Medical LLC | $496.30 | 2024 | Fusion |
| Abbvie INC. | $281.39 | 2024-2025 | |
| Madrigal Pharmaceuticals | $154.65 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $131.87 | 2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $127.25 | 2022-2023 | Xarelto |
| Glaxosmithkline, LLC. | $125.00 | 2021 | |
| Boston Scientific Corporation | $79.36 | 2025 | General - Hemostasis |
| Phathom Pharmaceuticals, INC. | $65.11 | 2025 | Voquezna |
| Janssen Biotech, INC. | $44.94 | 2024 | Stelara, Tremfya |
| Amarin Pharma, INC. | $35.49 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tsujung Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.